1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018; 378: 439–448.
2. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380: 45–56.
3. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017; 377: 2531–2544.
4. KYMRIAH (tisagenlecleucel) | FDA. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel (Ultimo accesso 25 gennaio 2020).
5. YESCARTA (axicabtagene ciloleucel) | FDA. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel (Ultimo accesso 25 gennaio 2020).
6. Kymriah | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah (Ultimo accesso 25 gennaio 2020).
7. Yescarta | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta#authorisation-details-section (Ultimo accesso 25 gennaio 2020).
8. AIFA approva la rimborsabilità della prima terapia CAR-T. https://www.aifa.gov.it/-/aifa-approva-la-rimborsabilita-della-prima-terapia-car-t (Ultimo accesso 25 gennaio 2020).
9. AIFA approva la rimborsabilità di una nuova terapia CAR-T. https://www.aifa.gov.it/-/aifa-approva-la-rimborsabilita-di-una-nuova-terapia-car-t (Ultimo accesso 25 gennaio 2020).
10. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 2019; 25: 625–638.
11. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 2019; 20: 31–42.
12. Abramson JS, Gordon LI, Palomba ML, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol 2018; 36: 7505–7505.
13. Abramson JS, McGree B, Noyes S, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N. Engl. J. Med. 2017; 377: 783–784.
14. Frigault MJ, Maus M V., Dietrich J, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood 2019; 134: 860–866.
15. Novo M, Ruff MW, Skrabek PJ, Lin Y. Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. Mayo Clin. Proc. 2019; 94: 2361–2364.
16. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188–195.
17. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat Rev Clin Oncol 2018; 15: 47–62.
18. Singh Ja, Beg S, Lopez-Olivo Ma. Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review. J Rheumatol 2011; 38: 10–20.
19. Deisseroth A, Ko C-W, Nie L, et al. FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease. Clin Cancer Res 2015; 21: 950–954.
20. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016; 127: 3321–3330.
21. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies. Cancer J 2014; 20: 119–122.
22. Liu S. Corticosteroids Do Not Influence the Efficacy and Kinetics of CAR-T Cells for B-Cell Acute Lymphoblastic Leukemia. Blood Cancer J 2020;10:15.
23. Gardner R, Ceppi F, Rivers J, et al. Preemptive Mitigation of CD19 CAR T Cell Cytokine Release Syndrome Without Attenuation of Anti-Leukemic Efficacy. Blood 2019; 134: 2149–2158.
24. Kenderian SS, Porter DL, Gill S. Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. Biol. Blood Marrow Transplant 2017; 23: 235–246.

Torna all'inizio    Torna al passo precedente